Fundz

Chance Pharmaceuticals raises new funding to accelerate development of innovative inhalation therapies. The funding will support Phase III clinical trials for CXG87 and strengthen their inhaled drug development capabilities.

PRIVATEMar 17, 2025

Round Type

Funding Round

HangzhouBiotechnologyTherapeutics

Investors

Qihang Venture CapitalHeda Health Fund

Description

Chance Pharmaceuticals, a clinical-stage biotechnology company, has announced the successful completion of a new round of financing. Heda Health Fund and Qihang Venture Capital participated in this round, which will support the advancement of Phase III clinical trials for CXG87 as well as the development of other inhalation powder formulations. Lighthouse Capital served as the exclusive financial advisor for this transaction. This funding marks a pivotal milestone for Chance Pharma as it enters a critical phase.

Quick answer

Chance Pharmaceuticals raised an undisclosed amount in a Funding Round round, dated March 17, 2025. Investors: Qihang Venture Capital and Heda Health Fund. Chance Pharmaceuticals is based in Hangzhou, Zhejiang, China.

How much did Chance Pharmaceuticals raise?
Chance Pharmaceuticals raised an undisclosed amount in a Funding Round round on March 17, 2025.
Who invested in Chance Pharmaceuticals?
Qihang Venture Capital and Heda Health Fund are named as investors in this round.
What does Chance Pharmaceuticals do?
Chance Pharmaceuticals is a clinical-stage biotechnology company dedicated to the research and development of innovative dry powder inhalation (DPI) therapies.
Where is Chance Pharmaceuticals based and how big is it?
Chance Pharmaceuticals is based in Hangzhou, Zhejiang, China. Fundz records about 51 employees.
Who are the decision-makers at Chance Pharmaceuticals?
Fundz holds 1 contact at Chance Pharmaceuticals. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Chance Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • Stately Bio raised $12M (Seed) on May 1, 2025.
  • Zucara Therapeutics raised $25M (Series B) on May 1, 2025.
  • Fore Biotherapeutics raised $37M on April 30, 2025.
  • Oratech Pharmaceuticals raised $37M (Corporate Round) on April 28, 2025.
  • Cycuria Therapeutics raised an undisclosed amount (Grant) on April 28, 2025.
  • Avidicure raised $50M (Seed) on April 27, 2025.

Who to call at Chance Pharmaceuticals, and when

A new round usually means Chance Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Chance Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Chance Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Chance Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Chance Pharmaceuticals

Location

Hangzhou, Zhejiang, China

About

Chance Pharmaceuticals is a clinical-stage biotechnology company dedicated to the research and development of innovative dry powder inhalation (DPI) therapies. The company's pipeline is supported by two core technology platforms: milling and mixing, and spray drying. It focuses on advancing a diverse portfolio of programs targeting respiratory diseases, central nervous system (CNS) disorders, and fibrotic diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Chance Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Chance Pharmaceuticals's next move

See what Strategic adds

Chance Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.